How is Rituxan Hycela administered?
Rituxan Hycela (rituximab and hyaluronidase human) is given via subcutaneous injection - an injection under the skin - in the stomach area. It is administered by a healthcare professional.
Rituxan Hycela contains rituximab, the same active ingredient as in Rituxan. But it has been formulated so that it can be given over 5-7 minutes via subcutaneous injection, rather than via intravenous (IV) infusion like Rituxan, which can take 3-6 hours.
Rituxan Hycela should only be administered after at least one full dose of a rituximab product has been administered via intravenous (IV) infusion because of the potential for hypersensitivity reactions and other side effects during the initial administration of rituximab products.
Before you receive Rituxan Hycela, an antihistamine and acetaminophen, and possibly a glucocorticoid medication, will be administered to help prevent side effects. After your injection you’ll be monitored for at least 15 minutes.
References
- Rituxan Hycela website. Prescribing information. Administration. [Accessed September 29, 20201]. Available from: https://www.rituxanhycela.com/hcp/dosing-and-administration/administration.html.
- NIH, National Cancer Institute. New Rituximab Formulation Approved for Some Lymphomas, Leukemia. July 14, 2017. [Accessed September 29, 2021]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-rituxan-hycela.
Read next
What is the difference between Rituxan and Rituxan Hycela?
Rituxan (rituximab) is administered intravenously (IV), while Rituxan Hycela is given subcutaneously (SC). Continue reading
What is CAR T-cell therapy and how does it work?
CAR T-cell therapy is a personalized treatment that uses a patient's own immune cells to fight certain cancers and autoimmune diseases. By harnessing and reprogramming a patient’s own immune cells, this therapy offers a new option for those who have not responded to conventional treatments.
Continue reading
What is the difference between Truxima and Rituxan?
Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). While both drugs are CD20-directed cytolytic antibodies used to treat non-Hodgkin’s lymphoma (NHL), Rituxan has additional FDA-approved indications beyond NHL. Continue reading
See also:
Related medical questions
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- Does Truxima make you gain weight?
- What are the names of the BTK inhibitors?
- What is the cost of Kymriah?
- What is the cost of Yescarta?
- What's the difference between Kymriah and Yescarta?
- How does Monjuvi work?
- What is Zydelig used for and how does it work?
- How is Monjuvi given / administered?
- What is the success rate of Epkinly?
- What is the survival rate of Kymriah?
- What is the success rate of Breyanzi?
- How is Kymriah administered?
- How is Yescarta administered?
- What type of drug is Copiktra?
- What type of drug is Yescarta (axicabtagene ciloleucel)?
- Prednisone: What are 12 Things You Should Know?
- What are CHOP and R-CHOP chemotherapy regimens?
- What causes infusion reactions to rituximab?
- Is Adcetris a chemotherapy drug?
- What is the success rate of Monjuvi?
Drug information
- Rituxan Hycela Information for Consumers
- Rituxan Hycela prescribing info & package insert (for Health Professionals)
- Side Effects of Rituxan Hycela (detailed)
Related support groups
- Rituxan Hycela (2 questions, 3 members)
- Follicular Lymphoma (21 questions, 15 members)
- Diffuse Large B-Cell Lymphoma (19 questions, 3 members)
- Chronic Lymphocytic Leukemia (CLL) (27 questions, 57 members)